Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 15/20 | 0.58 |
| ▸ | HTR4 | Q13639 | 15/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828465 | 1.00 | HTR3A (0.58) | HTR3AHTR4PARP1 | |
| SCHEMBL29401326 | 0.88 | HTR3A (0.59) | HTR3AHTR4PARP1 | |
| SCHEMBL828636 | 0.88 | HTR3A (0.59) | HTR3AHTR4PARP1 | |
| SCHEMBL1728203 | 0.87 | HTR3A (0.44) | HTR3AHTR4PARP1 | |
| SCHEMBL829163 | 0.86 | HTR4 (0.60) | HTR3AHTR4PARP1 | |
| SCHEMBL29399928 | 0.86 | HTR4 (0.60) | HTR3AHTR4PARP1 | |
| SCHEMBL829424 | 0.86 | HTR4 (0.76) | HTR3AHTR4PARP1 | |
| SCHEMBL29397821 | 0.84 | HTR3A (0.65) | HTR3AHTR4PARP1 | |
| SCHEMBL828472 | 0.84 | HTR3A (0.65) | HTR3AHTR4PARP1 | |
| SCHEMBL828678 | 0.84 | HTR4 (0.67) | HTR3AHTR4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.